Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis

BACKGROUND: Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 , a key negative regulator of T-cell activation approved by the Food and Drug Administration as of March 2011 for the treatment of metastatic melanoma. As a result of the up-regulation of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Venditti, Olga, De Lisi, Delia, Caricato, Marco, Caputo, Damiano, Capolupo, Gabriella Teresa, Taffon, Chiara, Pagliara, Elisa, Battisi, Sofia, Frezza, Anna Maria, Onetti Muda, Andrea, Tonini, Giuseppe, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350587/
https://www.ncbi.nlm.nih.gov/pubmed/25885696
http://dx.doi.org/10.1186/s12885-015-1074-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350587/
https://www.ncbi.nlm.nih.gov/pubmed/25885696
http://dx.doi.org/10.1186/s12885-015-1074-7

Ejemplares similares